This study aimed to characterize adverse drug reactions (ADRs) to hydroxychloroquine (HCQ) in the setting of COVID-19, occurring in Italy in the period March to May 2020. The analysis of the combination therapy with azithromycin or/and lopinavir/ritonavir, as well as a comparison with ADRs reported throughout 2019, was performed. Adverse drug reactions collected by the Italian National Network of Pharmacovigilance were analyzed for their incidence, seriousness, outcome, coadministered drugs and Medical Dictionary for Regulatory Activities classification. A total of 306 reports were gathered for the quarter of 2020: 54% nonserious and 46% serious, and half of the latter required either the hospitalization or its prolongation. However, most of them were either completely recovered (26%) or in the process of recovery (45%), except for nine fatal cases. Learners that complete this activity will be able to explain the ADRs associated with HCQ therapy with/without adjunct therapies targeting SARS-CoV-2 and practice evidence-based medicine in the setting of COVID-19 pandemic.
- Provider:American College of Clinical Pharmacology
- Activity Link: https://www.accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14
- Start Date: 2022-05-01 05:00:00
- End Date: 2022-05-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all